Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
164.85B
Market cap164.85B
Price-Earnings ratio
10.12
Price-Earnings ratio10.12
Dividend yield
3.49%
Dividend yield3.49%
Average volume
19.31M
Average volume19.31M
High today
$36.66
High today$36.66
Low today
$36.60
Low today$36.60
Open price
$35.41
Open price$35.41
Volume
326.57K
Volume326.57K
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.12
52 Week low$35.12

NVO News

Simply Wall St 7h
Did Hims & Hers' Novo Nordisk GLP-1 Partnership Just Shift Hims & Hers Health's Investment Narrative?

In March 2026, Hims & Hers Health announced a collaboration with Novo Nordisk to offer eligible customers a broad range of FDA-approved GLP-1 medications, inclu...

Did Hims & Hers' Novo Nordisk GLP-1 Partnership Just Shift Hims & Hers Health's Investment Narrative?
TipRanks 15h
Omeros reports Q4 EPS $1.22, consensus 36c

Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth quarter also includes a $136.0 mil...

Cheddar 16h
Novo Nordisk Launches Wegovy Subscription Plans to Lower Costs and Boost Patient Retention

Novo Nordisk Launches Wegovy Subscription Plans to Lower Costs and Boost Patient Retention Novo Nordisk is introducing multi-month subscription plans for its W...

Novo Nordisk Launches Wegovy Subscription Plans to Lower Costs and Boost Patient Retention

Analyst ratings

61%

of 36 ratings
Buy
30.6%
Hold
61.1%
Sell
8.3%

More NVO News

Benzinga 17h
Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan

Earlier in March, the U.S. Food and Drug Administration (FDA) approved a higher-dose version of Wegovy, marking an expansion of its treatment portfolio for adul...

Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
TipRanks 19h
Novo Nordisk Advances New Obesity and Diabetes Drug With Key China Study Completion

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decision...

TipRanks 23h
Novo Nordisk launches multi-month subscription program for Wegovy

07:47 EDT Novo Nordisk (NVO) launches multi-month subscription program for Wegovy Published first on TheFly – the ultimate source for real-time, market-moving...

CNBC 24h
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly

Key Points Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients pay lower, "pr...

Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly
Simply Wall St 1d
Hims Novo Nordisk GLP-1 Launch Ties Growth Story To Valuation Gap

Hims & Hers Health (NYSE:HIMS) has launched access to Novo Nordisk FDA-approved GLP-1 medications for eligible patients. The offering includes a range of GLP-1...

Hims Novo Nordisk GLP-1 Launch Ties Growth Story To Valuation Gap
TipRanks 2d
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 4d
Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program

Novo Nordisk (NYSE:NVO) has received an FDA National Priority Voucher tied to a higher dose of its obesity drug Wegovy. This is the fourth such voucher granted...

Novo Nordisk Voucher Win Meets Rising Scrutiny Of FDA Review Program

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.